AviadoBio Expands vMiX™ Precision Gene Silencing Platform Exclusive License Agreement with King’s College London Beyond Neurological Diseases to All Human Therapeutic Areas vMiX™ is a vectorized RNA ...
AviadoBio will combine its proprietary vMiX™ RNAi platform with Apertura’s novel human TfR1 capsid (TfR1 CapX™) to enable one-time gene silencing in the central nervous system AviadoBio will present ...
LONDON, June 16, 2026--(BUSINESS WIRE)--AviadoBio Ltd. ("AviadoBio"), a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for ...
Update follows recent positive AVB-406 preclinical data presented at ASGCT, supporting the broad therapeutic potential of the vMiX platform including initiation of clinical trials in 2026 ...
vMiX is a vectorized RNA interference (RNAi) platform combining knockdown, cell-specific expression with the flexibility to target multiple genes Update follows recent positive AVB-406 preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results